Cargando…
Toward Overcoming Treatment Failure in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA tre...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732378/ https://www.ncbi.nlm.nih.gov/pubmed/35003068 http://dx.doi.org/10.3389/fimmu.2021.755844 |
_version_ | 1784627574884794368 |
---|---|
author | Wang, Zhuqian Huang, Jie Xie, Duoli He, Dongyi Lu, Aiping Liang, Chao |
author_facet | Wang, Zhuqian Huang, Jie Xie, Duoli He, Dongyi Lu, Aiping Liang, Chao |
author_sort | Wang, Zhuqian |
collection | PubMed |
description | Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a “trial-and-error” approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data. |
format | Online Article Text |
id | pubmed-8732378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87323782022-01-07 Toward Overcoming Treatment Failure in Rheumatoid Arthritis Wang, Zhuqian Huang, Jie Xie, Duoli He, Dongyi Lu, Aiping Liang, Chao Front Immunol Immunology Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a “trial-and-error” approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data. Frontiers Media S.A. 2021-12-23 /pmc/articles/PMC8732378/ /pubmed/35003068 http://dx.doi.org/10.3389/fimmu.2021.755844 Text en Copyright © 2021 Wang, Huang, Xie, He, Lu and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Zhuqian Huang, Jie Xie, Duoli He, Dongyi Lu, Aiping Liang, Chao Toward Overcoming Treatment Failure in Rheumatoid Arthritis |
title | Toward Overcoming Treatment Failure in Rheumatoid Arthritis |
title_full | Toward Overcoming Treatment Failure in Rheumatoid Arthritis |
title_fullStr | Toward Overcoming Treatment Failure in Rheumatoid Arthritis |
title_full_unstemmed | Toward Overcoming Treatment Failure in Rheumatoid Arthritis |
title_short | Toward Overcoming Treatment Failure in Rheumatoid Arthritis |
title_sort | toward overcoming treatment failure in rheumatoid arthritis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732378/ https://www.ncbi.nlm.nih.gov/pubmed/35003068 http://dx.doi.org/10.3389/fimmu.2021.755844 |
work_keys_str_mv | AT wangzhuqian towardovercomingtreatmentfailureinrheumatoidarthritis AT huangjie towardovercomingtreatmentfailureinrheumatoidarthritis AT xieduoli towardovercomingtreatmentfailureinrheumatoidarthritis AT hedongyi towardovercomingtreatmentfailureinrheumatoidarthritis AT luaiping towardovercomingtreatmentfailureinrheumatoidarthritis AT liangchao towardovercomingtreatmentfailureinrheumatoidarthritis |